Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Colorectal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Metastatic Colorectal Cancer....
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for B-Cell Non-Hodgkin Lymphoma....
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Hodgkin Lymphoma (B-Cell...
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...